SCHEMBL30970711

SCHEMBL30970711

CCOc1cc(Br)cc2c(CCl)n[nH]c(=O)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 1/20 0.38
▸ PDE1A P54750 1/20 0.38
▸ PDE1B Q01064 1/20 0.38
▸ PDE3B Q13370 1/20 0.38
▸ PDE1C Q14123 1/20 0.38
▸ PDE3A Q14432 1/20 0.38
▸ PRMT5 O14744 6/20 0.36
▸ WDR77 Q9BQA1 5/20 0.35
▸ PTK6 Q13882 1/20 0.35
▸ IGF1R P08069 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ AR P10275 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27002463 1.00 ADORA1 (0.38) ADORA1PDE1APDE1BPDE3BPDE1C
SCHEMBL27002343 0.87 PRMT5 (0.45) ADORA1PDE1APDE1BPDE3BPDE1C
SCHEMBL29915218 0.85 POLB (0.46) ADORA1PDE1APDE1BPDE3BPDE1C
SCHEMBL27002563 0.85 POLB (0.46) ADORA1PDE1APDE1BPDE3BPDE1C
SCHEMBL30752919 0.81 PARP1 (0.32) PARP1
SCHEMBL27002499 0.81 ADORA1 (0.41) ADORA1PDE1APDE1BPDE3BPDE1C
SCHEMBL31496929 0.81 PRMT5 (0.34) ADORA1PDE1APDE1BPDE3BPDE1C
SCHEMBL23087286 0.80 ADORA1 (0.39) ADORA1PDE1APDE1BPDE3BPDE1C
SCHEMBL29915065 0.79 PRMT5 (0.61) PRMT5WDR77PARP1GAA
SCHEMBL27002364 0.79 PRMT5 (0.61) PRMT5WDR77PARP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors MIRATI THERAPEUTICS INC (US) 2024-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors PRMT1, PRMT5, PRMT6 ADORA1 3288/4885PDE1A 757/4885PDE1B 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback